What does 'research use only' actually mean?

Does the label mean a regulator has reviewed the product?

No. The FDA's 2013 guidance on research use only and investigational use only in vitro diagnostics states that such labelling must be consistent with the manufacturer's intended use of the device [5]. The Federal Register notice announcing that guidance describes the problem it was written to solve: mislabelling had led to diagnostic use of products whose performance characteristics were unproven [6].

The label flags that a product has not been through the review its end use would require. It does not record that any review took place. It is closer to a disclaimer of regulatory status than a certificate of one.

Can a seller make a product legal for human use by labelling it 'research use only'?

No, and this exact pattern has been enforced against. 21 CFR 201.128 defines intended use by objective evidence rather than by label text. Intent can be shown by the seller's own statements, by the design or composition of the article, or by the circumstances surrounding its distribution, including advertising [3]. The statutory definition agrees: an article is a drug if it is intended to affect the structure or any function of the body, or intended for the diagnosis, cure, mitigation, treatment or prevention of disease [4].

On 24 August 2026 the FDA issued warning letters to five online peptide sellers on the same day. One letter states that despite labelling marketing the products for research use only and not for human consumption, evidence from the seller's website established that the products were intended to be drugs for human use [7]. The evidence cited was ordinary marketing copy: descriptions of metabolic and recovery effects, references to named conditions, and the sale of reconstitution water alongside the vials.

Import Alert 66-41 gives the agency a parallel route at the border, authorising detention without physical examination of unapproved new drugs promoted in the United States [8]. Neither route turns on what the vial says.

Is there a lawful route for a peptide to reach a person without full approval?

There is one, and it runs through pharmacy compounding law rather than through labelling. Under 21 U.S.C. 353a(b)(1)(A), a bulk substance used in 503A compounding must comply with an applicable United States Pharmacopeia or National Formulary monograph where one exists, and must be made by an establishment registered with the FDA [9]. The agency sorts nominated bulk substances into three categories: no significant safety risk identified, significant safety risk identified, and insufficient information to evaluate [10].

BPC-157 sits in a nominated but withdrawn status on the agency's safety risk list. The stated concerns are immunogenicity for certain routes of administration, complexity around peptide-related impurities and characterisation of the active ingredient, and limited safety information for the proposed routes [11].

The question is live. The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to reconsider seven peptides for the 503A bulks list, among them BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon [12]. The committee recommended six of the seven, against the agency staff's own written position [13, 19]. As of September 2026 the FDA's bulk substances safety risk list still carries an April 2026 date and does not reflect the vote, and no Federal Register notice adding these peptides was located [11]. A committee recommendation is advice. It is not a change in law.

What does 'research use only' mean under EU law?

The EU splits the question the same way. Regulation (EU) 2017/746 excludes products for general laboratory use and research use only products from its scope, but only where the manufacturer does not specifically intend them for in vitro diagnostic examination [14]. Recital 7 treats research use only products as a category distinct from regulated diagnostic devices [15].

For medicines, Directive 2001/83/EC defines a medicinal product by what it is intended to do to the body, carves out products intended for research and development trials, and still requires under Article 6(1) that no medicinal product be placed on the market of a Member State without a marketing authorisation [16]. As in the United States, the label narrows an exemption. It does not create permission to sell a compound for people to use on themselves.

Does the label tell you anything about what is actually in the vial?

No. A 2024 analysis in the Journal of Medical Internet Research tested semaglutide products bought from online sellers without a prescription, the same unregulated supply chain that research use only peptides move through. Every sample was assessed as substandard or falsified. Measured content ran 28.56 to 38.69 percent above the labelled amount, purity fell between 7.7 and 14.37 percent against a claimed 99 percent, and endotoxin was present in all samples tested [18].

That study covered one compound, so read it as evidence about the supply chain rather than about any specific peptide. No peer reviewed purity or content analysis specific to BPC-157 or TB-500 was located. That absence is itself part of the answer: the label guarantees nothing, and no public dataset fills the gap.

Does 'research use only' mean anything in competitive sport?

Yes, and here the answer is blunt. The WADA Prohibited List in force from 1 January 2026 includes category S0, non-approved substances, covering any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use. Substances in S0 are prohibited at all times, and BPC-157 is named as an example [17].

For an athlete under the WADA code, the absence of regulatory approval is itself the basis for the ban. The research label creates no grey area at all.

What would change this answer

A final FDA decision or Federal Register notice following the July 2026 committee votes. A guidance document addressing research use only labelling on peptides sold to consumers rather than on diagnostic reagents. A published purity analysis of the specific peptides most often sold under this label. An update to the WADA S0 category. Any one of these would require parts of this answer to be rewritten.